Xcelerated Recovery® is a physician-founded perioperative nutrition company focused on improving surgical outcomes through targeted metabolic optimization. Our evidence-based formulations address muscle loss, wound healing, and infection risk, integrating seamlessly into perioperative protocols to support recovery and enhance patient function following orthopedic procedures.
VIATRIS
VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and improving patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities. | Viatris Inc. is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. | Booth 1650 – Yupelri (COPD) Booth 1765 – Tobi Podhaler (Cystic Fibrosis) Expo 1569 – Tobi Podhaler (Cystic Fibrosis) – Informational Sessions VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions, and improving patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities. | VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and leveraging our collective expertise to improve patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver quality medicines to patients when and where they need them.
Vertex Pharmaceuticals
Vertex invests in scientific innovation to create transformative medicines for people with serious diseases. Through cutting-edge science across multiple modalities, it has approved medicines that treat the underlying causes of multiple diseases and conditions and has a broad and deep clinical pipeline. Learn more at www.vrtx.com. | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for other serious diseases like type 1 diabetes, APOL1-mediated kidney disease and IgA nephropathy. | xxx | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for serious kidney diseases, including APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy and autosomal dominant polycystic kidney disease.
Stiehl Tech LLC
Stiehl Tech LLC is a medical device company that has developed a new peristaltic pump irrigation system for use in surgical sites, traumatic fractures and wounds, and any infected chronic wound. We have increased the pressure to 12 PSI (ave) and flow rate of 1800 ccs/minute. With vector spray 60 degrees, we substantially increase biofilm bacteria removal compared to pulsatile irrigation. The pump becomes a durable item reducing the unit cost compared to standard pulsatile irrigator.
SpringWorks Therapeutics
SpringWorks Therapeutics is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with rare tumors. We scrutinize promising molecules from every angle to unlock their full potential. We forge collaborations with industry and academic innovators to multiply the opportunities for success. And we build our company with exceptional people who press beyond “good enough” to make a profound impact. In a word, we are tenacious.
RepPrep.ai
RepPrep.ai is a purpose-built AI platform for medical sales teams, transforming physician, claims, and research data into actionable insights and pre-call plans within seconds. With seamless integration, customized datasets, and continuously updated information, RepPrep.ai equips organizations to optimize targeting, enhance ROI, and streamline sales effectiveness.
Pacira BioSciences, Inc.
Pacira BioSciences, Inc. is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
OVIAL Nutrition
The Ovial Nutrition Kit is a complete 6-week nutritional system developed by surgeons to support orthopedic patients throughout their recovery journey. Designed to help prepare the body before surgery and optimize healing afterward, OVIAL focuses on the core biological needs of recovery: muscle preservation, inflammation support, tissue repair, nerve health, mobility, immune balance, and improved sleep quality.
Osteal Therapeutics
Osteal Therapeutics is a privately held, clinical-stage biopharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences. The company is leveraging the ability of concentrated, locally delivered antimicrobials to treat the bacterial biofilms typically responsible for musculoskeletal infections while minimizing off-target tissue exposure and associated adverse effects. Osteal employs a low-risk development strategy by using approved drugs with long histories of safety and efficacy as candidates for new routes of local delivery. The company’s lead candidate, VT-X7 KIT, is in late-stage clinical development to treat periprosthetic joint infections, a serious complication of joint replacement surgery. For more information, please visit: www.ostealtx.com.